This landmark agreement finally ends decades of Britain freeloading off American patients who've been forced to subsidize the world's drug costs. The deal secures zero tariffs on £5 billion worth of U.K. pharmaceutical exports while ensuring fair pricing that will fuel innovation and bring cutting-edge treatments to patients.

The U.S.-U.K. deal forces taxpayers to pay an extra £3 billion while the NHS budget for medicines balloons from 9.5% to 12%. It raises drug prices by 25% and weakens cost-effectiveness standards that protected patients from overpriced treatments, all to appease Trump's demand that Europe subsidize U.S. pharmaceutical profits.